Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads brain scans to spot tumors without a biopsy

NCT ID NCT07703761

Knowledge-focused Sponsor: Università degli Studi di Trento Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study explores whether artificial intelligence can analyze MRI scans to detect, map, and characterize gliomas—a common type of brain tumor—without needing an invasive biopsy. Researchers will collect existing MRI and clinical data from about 700 patients across Italy to train AI models. The goal is to help doctors make faster, more accurate treatment decisions and potentially reduce the need for surgical tissue sampling.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-driven analysis of brain MRI data using convolutional neural networks, recurrent neural networks, and vision transformers
What this could lead to
If successful, this could lead to faster, non-invasive diagnosis of brain tumors and more personalized treatment planning, reducing the need for biopsies.
What could go wrong
This is an observational study using existing data, so the AI models may not perform as well in real-world settings. Results are exploratory and not yet validated for clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of approximately 700 adult patients (100 per center) aged 18 to 60 years, diagnosed with brain glioma between 2019 and 2024 across seven specialized Italian neurosurgical centers. All participants underwent surgical tumor resection, with or without subsequent radiotherapy or chemotherapy. Only patients with high-quality MRI scans and essential clinical information are included. The study uses retrospective data, and where possible, informed consent is obtained. If consent cannot be collected due to patient death or unreachability, inclusion may still occur under ethically approved conditions. Data are pseudonymized and used to train and validate AI models.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Imaging (MRI) of confirmed glioma diagnosis in the period 2019-2024, for whom cancer types and stages, from diagnosis to post-treatment are available * Having undergone a full brain tumor resection operation, followed or not by treatment with RT or CHT * Adults aged 18 to 60 years * Informed consent available, when possible and applicable Exclusion Criteria: * Poor quality or artifact-laden MRI images * Lack of a minimal set of clinical information * Explicit refusal of consent (if possible to obtain) * Age under 18 years or over 60 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer disease glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA Glioma (diagnosis)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CISMed, Centre for Medical Sciences

    RECRUITING

    Trento, 38122, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.